Scribd Logo
Upload

Welcome to Scribd!

  • Lyrica Fails in Pain Trials

    Uploaded by

    Dr. Robert Zhang
    10 views1 page
    Lyrica is very expensive compared to an older drug (neurontin), they are virtually the same drug and neither one works that well. Some patients may still respond to lyrica as a first line agent.

    Original Description:

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    Lyrica is very expensive compared to an older drug (neurontin), they are virtually the same drug and neither one works that well. Some patients may still respond to lyrica as a first line agent.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    10 views1 page

    Lyrica Fails in Pain Trials

    Uploaded by

    Dr. Robert Zhang
    Lyrica is very expensive compared to an older drug (neurontin), they are virtually the same drug and neither one works that well. Some patients may still respond to lyrica as a first line agent.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    Pain Management Specialist: May 2012

    Share

    Report Abuse

    Next Blog

    Create Blog

    Sign In

    Pain Management Specialist


    Wednesday, May 9, 2012 Blog Archive 2012 (3) August (1) May (1) Lyrica Fails in Pain Trials April (1)

    Lyrica Fails in Pain Trials


    Just read the article "Lyrica Fails in Pain Trials", something I dont think many physicians are surprised about. In my experience the chances of lyrica working well for radicularpain or painful peripheral neuropathy is more of an exception rather than the norm. It makes you appreciate the power of marketing. Lyrica is very expensive compared to an older drug (neurontin), they are virtually the same drug and neither one works that well and yet lyrica is now widely prescribed and preferred. I doubt these recent findings will change our reliance on lyrica only because we do not have much better options. There are other medications for nerve pain in the form certain antidepressants but they cannot be used in every one due to certain side effects and drug-drug interactions. In addition thepatients used for the trial had already failed another medication for neuropathic pain. So while these patients will not benefit from lyrica due to a variety of reasons such as the severity of the neuropathy, some patients may still respond to lyrica as a first line agent. Posted by Dr. Robert Zhang at 8:25 PM No comments:

    About Me Dr. Robert Zhang Dr. Robert Yu-Fan Zhang is an Interventional Pain Management Specialist with extended expertise in treating back pain, head and neck pain, and cancer pain. He is board certified in anesthesiology and fellowship trained in interventional pain management. After graduating from Albert Einstein College of Medicine, he completed his residency at Yale New Haven Hospital and pain management fellowship at University of California of San Francisco Mount Zion Hospital. After practicing as an attending for Kaiser Permanente in California, he now serves as the Director of Pain Management at Queens Medical Associates. Dr. Zhang has extensive experience in a variety of interventions including epidurals, facet therapies, nerve blocks, neurolytic procedures, and radiofrequency ablation. View my complete profile

    Recommend this on Google

    Newer Posts

    Home
    Subscribe to: Posts (Atom)

    Older Posts

    Awesome Inc. template. Powered by Blogger.

    http://drrobertzhang.blogspot.com/2012_05_01_archive.html[8/9/2012 3:14:59 PM]

    You might also like